Is ONC a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for BeOne Medicines (ONC) rests on BRUKINSA taking share in B-cell cancers: BRUKINSA global sales reached ~$1.2 billion in the second quarter of 2026, up 31% year over year, with U.S. The bear case rests on concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. Analysts covering it publish targets from $385.00 to $561.30 against a $411.29 share price on November 16, 2026, so even the professionals disagree by 38% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
ONC key stats
At $411.29 on November 16, 2026, BeOne Medicines (ONC) has a market cap of $47.0B and a P/E of 52.7 on trailing earnings (38.1 on forward earnings).
- Market cap
- $47.0B
- P/E (trailing)
- 52.7
- P/E (forward)
- 38.1
- EPS (trailing 12 months)
- $7.80
- Price to book
- 8.1
- Beta
- 0.63
Market cap, P/E and yield are measured at the $411.29 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with BeOne Medicines (ONC)?
The last two weeks for BeOne Medicines, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- ONC closed at $411.29 on November 16, 2026, down 1.4% over the past five trading days (from $417.33).
- On November 5, 2026, BeOne Medicines filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 5, 2026, BeOne Medicines filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 6, 2026, RBC Capital raised its target to $465.00 from $459.00 (Outperform).
- On November 6, 2026, Truist Securities raised its target to $448.00 from $420.00 (Buy).
- On November 6, 2026, Barclays raised its target to $446.00 from $415.00 (Overweight).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
BeOne Medicines is a global oncology company built around one large drug. BRUKINSA (zanubrutinib), a BTK inhibitor used in chronic lymphocytic leukemia and other B-cell cancers, produced ~$1.2 billion of the ~$1.68 billion in product revenue it booked in the second quarter of 2026. Around it sit TEVIMBRA (tislelizumab), a PD-1 antibody; BEQALZI (sonrotoclax), a BCL2 inhibitor that won U.S. accelerated approval in relapsed or refractory mantle cell lymphoma; ZIIHERA (zanidatamab) in HER2-positive gastroesophageal cancer; and in-licensed Amgen products sold in China. The company was BeiGene until recently. Its Nasdaq listing began trading under symbol ONC instead of BGNE on January 2, 2025, and effective May 27, 2025 the company moved its jurisdiction of incorporation from the Cayman Islands to Switzerland and took the BeOne Medicines name. What a U.S. holder actually owns is an American Depositary Share representing 13 ordinary shares, the same shares listed in Hong Kong (06160) and, as RMB shares, on Shanghai's STAR Market (688235). The investment picture is a biotech that has finished crossing into profit. Trailing twelve-month revenue of ~$6.13 billion came with ~$656 million of GAAP net income after years of losses, and management raised 2026 revenue guidance to $6.6 billion to $6.8 billion with GAAP operating income of $1.0 billion to $1.1 billion. Second-quarter gross margin reached 90% of product sales, free cash flow was ~$435 million, and the balance sheet holds ~$5.28 billion of cash against ~$1.07 billion of debt. The argument is over what that stream is worth at roughly 6.8 times trailing sales and about 66 times trailing GAAP earnings (about 36 times forward estimates) as of October 16, 2026, when the ADS closed near $368, up about 18% year to date and close to its 52-week high of about $385. Supporters cite BRUKINSA taking share from Imbruvica and Calquence, a revenue base now ~54% U.S. and only ~30% China, and a deep internally discovered pipeline. Skeptics cite dependence on a single molecule, an AbbVie trade secret suit that survived dismissal, and a company whose research, manufacturing and selling straddle two governments rewriting the rules on each other. Two policy items landed on August 31, 2026. BeOne announced a voluntary agreement with the U.S. government under which it joins the GENEROUS Medicaid model and commits to pricing future FDA-approved products in line with other key developed markets, and an onshoring agreement that secured an exemption from Section 232 pharmaceutical tariffs. Alongside it, a $300 million expansion of the Hopewell, New Jersey site takes total U.S. manufacturing investment past $1 billion. The same day it released new Phase 3 survival data supporting ZIIHERA-containing regimens in first-line HER2-positive gastroesophageal cancer. Third-quarter results are expected around November 5, 2026, with consensus near $1.76 billion of revenue and $1.88 of EPS per ADS.
The bull case: what would have to be true for $561.30
The most optimistic published target on ONC is $561.30, +36.5% from the $411.29 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. BRUKINSA taking share in B-cell cancers
BRUKINSA global sales reached ~$1.2 billion in the second quarter of 2026, up 31% year over year, with U.S. sales of ~$893 million growing at the same rate. The share is coming from older BTK inhibitors, principally AbbVie and Johnson & Johnson's Imbruvica and increasingly AstraZeneca's Calquence. Positive Phase 3 MANGROVE results in previously untreated mantle cell lymphoma and 78-month SEQUOIA follow-up in treatment-naive CLL feed first-line submissions the company has guided to in the second half of 2026.
2. Costs growing slower than revenue
Second-quarter revenue rose 30% while total GAAP operating expenses rose 13%, which turned ~$88 million of prior-year GAAP operating income into ~$325 million. SG&A fell to 35% of product sales from 41%, and gross margin improved to 90% as the mix tilted toward global BRUKINSA. Full-year GAAP operating income guidance was raised to $1.0 billion to $1.1 billion, roughly doubling the range given a year earlier.
3. A pipeline meant to outlive one molecule
BEQALZI (sonrotoclax) has now cleared FDA accelerated approval in relapsed or refractory mantle cell lymphoma, and tacabrutideg, the BTK degrader, has a potential Phase 2 submission guided for the second half of 2026. Solid tumor work includes BGB-43395 (CDK4 inhibitor), now in a Phase 3 first-line breast cancer study, plus the B7-H4 antibody-drug conjugate BG-C9074 and the GPC3 bispecific BGB-B2033, both slated to start registrational trials.
4. Revenue mix moving away from China
Second-quarter revenue split ~$914 million U.S., ~$506 million China, ~$209 million Europe and ~$76 million rest of world. Europe grew 37% and rest of world 114%, both faster than China's 17%, of which roughly 7 points came from a stronger renminbi. A company that started as a China biotech now books more than half its revenue in the United States, which changes both its regulatory profile and how the market frames its policy risk. The August 2026 onshoring agreement and Section 232 tariff exemption, backed by more than $1 billion of cumulative U.S. manufacturing investment, reduce one channel of that risk, at the cost of a commitment to price future U.S. launches in line with other developed markets.
The bear case: what would have to be true for $385.00
The most pessimistic published target is $385.00, -6.4% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks BeOne Medicines is worth if the risks below bite instead of the drivers above.
Concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. Zydus filed an ANDA with Paragraph IV certifications against certain BRUKINSA Orange Book patents in early 2026, though it has not challenged the composition of matter patent that runs to 2034. AbbVie's trade secret complaint over the BTK degrader program, including tacabrutideg, survived a motion to dismiss on May 12, 2026 and remains pending with no trial date. About 30% of revenue and a large share of manufacturing and clinical operations sit in China, leaving the company exposed to trade-status changes and U.S. or Chinese action against firms with large operations in both. The August 2026 pricing agreement exempts BeOne from Section 232 pharmaceutical tariffs but ties future U.S. launch prices to other developed markets, which could cap the upside on new products. The valuation, near 66 times trailing GAAP earnings on a profit record barely a year old, assumes the growth and the margin improvement both continue.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ONC already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ONC
27 analysts cover ONC, with an average target of $462.19 (+12.4% against $411.29) and a split of 26 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ONC forecast and price target page.
How is ONC valued?
Market cap, P/E and dividend yield at today's price are in the ONC key stats above. The business figures below come from BeOne Medicines's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$6.13B (Q2 2026 up ~30% YoY)
- Q2 2026 revenue: ~$1.71B
- GAAP net income (TTM): ~$656M (FY2025 was ~$287M, FY2024 a ~$645M loss)
- Q2 2026 diluted EPS per ADS: ~$2.05 GAAP vs ~$1.63 estimate; ~$3.84 adjusted
- Q3 2026 consensus (~Nov 5): ~$1.76B revenue, ~$1.88 EPS per ADS
As of October 2026: Quarterly figures come from the Form 10-Q for the quarter ended June 30, 2026 and the Q2 2026 earnings release; market figures are Yahoo Finance data as of October 16, 2026. At about $41.9 billion, the ADS trades near 6.8 times trailing sales and 66 times trailing GAAP earnings, but about 36 times the forward estimate, since analysts expect EPS per ADS to reach roughly $7.64 in 2026 and $10.25 in 2027. Per-ADS figures are 13 times the per-ordinary-share figures, which is why a screener showing EPS of $0.16 and one showing $2.12 can both be right.
How do you decide if ONC is a buy?
Whether ONC is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ONC indirectly through an index or sector ETF before adding more.
What would change your mind on ONC
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: BRUKINSA taking share in B-cell cancers stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ONC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ONC against your real portfolio and see your actual exposure before deciding.
Your questions about BeOne Medicines
Ask Walnut's AI anything about ONC and see how it fits what you own.
FAQ
Is ONC a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on BRUKINSA taking share in B-cell cancers, with revenue (ttm) at ~$6.13B (Q2 2026 up ~30% YoY). The bear case rests on concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. Analysts covering it are spread from $385.00 to $561.30, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ONC?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $385.00, -6.4% from the $411.29 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for ONC?
+
BRUKINSA taking share in B-cell cancers. BRUKINSA global sales reached ~$1.2 billion in the second quarter of 2026, up 31% year over year, with U.S. The most optimistic analyst target on ONC is $561.30, +36.5% from the $411.29 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for ONC?
+
Concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. Zydus filed an ANDA with Paragraph IV certifications against certain BRUKINSA Orange Book patents in early 2026, though it has not challenged the composition of matter patent that runs to 2034. AbbVie's trade secret complaint over the BTK degrader program, including tacabrutideg, survived a motion to dismiss on May 12, 2026 and remains pending with no trial date. About 30% of revenue and a large share of manufacturing and clinical operations sit in China, leaving the company exposed to trade-status changes and U.S. or Chinese action against firms with large operations in both. The August 2026 pricing agreement exempts BeOne from Section 232 pharmaceutical tariffs but ties future U.S. launch prices to other developed markets, which could cap the upside on new products. The valuation, near 66 times trailing GAAP earnings on a profit record barely a year old, assumes the growth and the margin improvement both continue. The most pessimistic published target is $385.00, -6.4% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does BeOne Medicines do?
+
BeOne Medicines, the Swiss-domiciled oncology company formerly known as BeiGene, is built around BRUKINSA, a BTK inhibitor taking share in blood cancers.
What would have to change for ONC to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (BRUKINSA taking share in B-cell cancers) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does BeOne Medicines do?
+
BeOne discovers, develops, manufactures and sells cancer medicines worldwide. Its lead product is BRUKINSA (zanubrutinib), a BTK inhibitor for B-cell blood cancers such as chronic lymphocytic leukemia and mantle cell lymphoma. It also sells the PD-1 antibody TEVIMBRA, the BCL2 inhibitor BEQALZI, ZIIHERA in HER2-positive gastroesophageal cancer, and several in-licensed Amgen products in China.
How does BeOne make money?
+
Almost entirely from product sales. Net product revenue was ~$1.68 billion in the second quarter of 2026, of which BRUKINSA was ~$1.2 billion, TEVIMBRA ~$229 million and the Amgen in-licensed products ~$157 million. Other revenue, mostly collaboration income, was ~$25 million. Gross margin on product sales ran at 90% in the quarter.
What is the full legal company name behind the ticker ONC?
+
BeOne Medicines Ltd., known in German as BeOne Medicines AG, incorporated in Switzerland with offices at Aeschengraben 27 in Basel. It was BeiGene, Ltd., a Cayman Islands company, until the redomiciliation took effect on May 27, 2025. The Nasdaq ticker changed from BGNE to ONC earlier, on January 2, 2025. Its SEC filer identifier is CIK 0001651308.
Walnut is informational, not investment advice, and gives no verdict on ONC. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.